Avid Bioservices Inc (CDMO)

[entdoc]

"classic post",2009: "Bavi better than excisional biopsy? When dealing with small tumors, whether benign or malignant, instead of taking "a piece" of the tumor, or a punch biopsy, and sending fragment to the lab, a surgeon attempts simultaneous diagnostic and curative measure by removing the lesion with an adequate cuff of normal tissue around it so that which is sent to the pathologist is the entire problem. There remains no treatment decision. The problem is in the specimen container...solved--cured. What is unique about PPHM's anti-PS program, its selling point, is that it acts as a diagnostic AND treatment tool. Most important, it is safe, efficious, and specific. Bavi's "chemo-attractant properties" calls in the body's immune-mediating cells to cancer which has heretofore been considered "safe", or "self", and evaded immune surveilance. These special body white blood cells attack the cancer which has escaped immune surveilance. In addition to immune-stimulating, chemo-irradiation treatment synergist Bavituximab, PPHM's pipeline includes a double-fisted fully-humanized anti-PS monoclonal antibody (MAB) that targets an exclusive docking site, -PS, an everted lipoprotein on the cell surface of cancer blood vessels, cancer cells, and virally-infected cells, and is capable of carrying contrast agents (and/or tumorcidal agents)on the arm not used for docking to -PS. Mind-boggling. Why isn't this available yet?